A review of the available information was performed.The manufacturing records for the onxaap-23 sn [serial number] (b)(4) were reviewed and it was confirmed that all records were controlled, available for review, and met all specifications.All lots passed functional testing and met release specifications.(b)(6) male patient implanted with onxaap-23 sn (b)(4) on (b)(6) 2018 indicated for ascending aortic dissection involving via emergent procedure finding "extensive aortic dissection all the way down to the aortic valve with severe ai on intraoperative tee prior to cardiopulmonary bypass [cpb]." the onxaap-23 was implanted and patient was weaned from cpb.The patient died same day intraoperatively.Op notes state "bleeding initially appeared to be ceasing and there was good cardiac rhythm and good indices" but then "bleeding became apparent somewhere posteriorly at the proximal anastomosis area.Multiple sutures were applied trying to stop the bleeding.This was unsuccessful.The patient developed bradycardia and a pea." it is possible that the death was due to the trauma of surgery, but there is no objective evidence to indicate what contribution, if any, the valve or the surgery had to the cause of death.Surgical death is a rare, but recognized potential complication associated with aortic valve replacement [instructions for use].As of 2016, the sts database indicated an operative mortality of 2% for aortic valve replacement procedures [sts].There is no evidence to indicate what, if any, relationship the valve had to the death of the patient.No further action is warranted at this time.
|